By Sneha S K and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an ...

By Sneha S K and Sriparna Roy (Reuters) - The U.S. Food and Drug Administration said on Friday that it has approved an ...

This was the stock's second consecutive day of gains.

Truist raised the firm’s price target on Bristol Myers (BMY) to $65 from $62 and keeps a Buy rating on the shares as part of a broader research ...

The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type ...

GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab, Bristol Myers Squibb's anti-PD-1 therapy, as ...

Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...

CytomX’s workforce cuts could leave the biotech with fewer than 75 employees as it focuses resources on its wholly owned ...

The U.S. Justice Department said on Tuesday it entered an agreement to share $50 million in forfeited assets with Estonia in ...

Bristol Myers Squibb’s Cobenfy achieved an 8.4-point PANSS improvement over placebo after five weeks in a phase 3 trial that ...

About Fexlamose Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve lung function, lessen symptoms and improve quality of life.

Emerging evidence supports the argument that psoriatic arthritis arises from two pathways and that affected immune cells may ...